2.55

6.69% 0.16

After Hours: 2.51 -0.04 -1.57%

Organogenesis Holdings Inc (ORGO)

Overview News Price History Option Chain Financials Discussions Forecast

Organogenesis Holdings Inc stock is traded at $2.55, with a volume of 410.97K. It is up +6.69% in the last 24 hours and up +4.94% over the past month. Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Previous Close:

$2.39

Open:

$2.41

24h Volume:

410.97K

Relative Volume:

0.40

Market Cap:

$328.12M

Revenue:

$514.70M

Net Income/Loss:

$2.72M

P/E Ratio:

-16.05

EPS:

-0.1589

Net Cash Flow:

$17.08M

1W Performance:

-3.04%

1M Performance:

+4.94%

6M Performance:

-36.09%

1Y Performance:

-49.30%

1-Day Range:

$2.41

$2.595

1-Week Range:

$2.32

$2.69

52-Week Range:

$2.04

$7.0771

Organogenesis Holdings Inc Stock (ORGO) Company Profile

Name

Organogenesis Holdings Inc

Sector

Healthcare (1074)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

781-575-0775

Address

85 DAN ROAD, CANTON, MA

Employee

854

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ORGO's Discussions on Twitter

Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORGO Organogenesis Holdings Inc	2.55	307.53M	514.70M	2.72M	17.08M	-0.1589
TAK Takeda Pharmaceutical Co Adr	17.44	55.06B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.94	43.07B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.08	35.88B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.92	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	527.94	26.32B	3.17B	1.29B	1.01B	27.09

Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Initiated	Lake Street	Buy
Feb-07-24	Initiated	Cantor Fitzgerald	Overweight
Jun-15-23	Initiated	Morgan Stanley	Equal-Weight
May-24-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Aug-10-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-10-20	Initiated	SVB Leerink	Outperform
Aug-26-19	Resumed	Credit Suisse	Outperform
May-02-19	Initiated	Credit Suisse	Outperform
Apr-17-19	Initiated	Oppenheimer	Outperform
Apr-11-19	Initiated	SunTrust	Buy

View All

Organogenesis Holdings Inc Stock (ORGO) Latest News

Jul 27, 2026

Organogenesis reports positive trial results for wound care product - Investing.com

Jul 27, 2026

Organogenesis Announces Published RCT Results Showing Affinity Plus Standard of Care Improves Closure Rates in Complex Venous Leg Ulcers - Quiver Quantitative

Jul 27, 2026

Peer-reviewed Affinity trial finds higher closure in leg wounds over 24 months - Stock Titan

Jul 27, 2026